Biotechnology Assets Financials
| BST Stock | 0.34 0.01 3.03% |
Biotechnology |
Understanding current and past Biotechnology Assets Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biotechnology Assets' financial statements are interrelated, with each one affecting the others. For example, an increase in Biotechnology Assets' assets may result in an increase in income on the income statement.
Please note, the presentation of Biotechnology Assets' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biotechnology Assets' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biotechnology Assets' management manipulating its earnings.
| Foreign Associate | USA |
| Instrument | Spain Stock View All |
| Exchange | Madrid Exchange |
| ISIN | ES0184980003 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
You should never invest in Biotechnology Assets without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Biotechnology Stock, because this is throwing your money away. Analyzing the key information contained in Biotechnology Assets' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Biotechnology Assets Key Financial Ratios
Biotechnology Assets' financial ratios allow both analysts and investors to convert raw data from Biotechnology Assets' financial statements into concise, actionable information that can be used to evaluate the performance of Biotechnology Assets over time and compare it to other companies across industries.| Return On Equity | -0.74 | |||
| Return On Asset | -0.0647 | |||
| Number Of Employees | 33 | |||
| Beta | 1.51 |
Biotechnology Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Assets's current stock value. Our valuation model uses many indicators to compare Biotechnology Assets value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotechnology Assets competition to find correlations between indicators driving Biotechnology Assets's intrinsic value. More Info.Biotechnology Assets SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biotechnology Assets by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biotechnology Assets' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Biotechnology Assets Systematic Risk
Biotechnology Assets' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biotechnology Assets volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Biotechnology Assets correlated with the market. If Beta is less than 0 Biotechnology Assets generally moves in the opposite direction as compared to the market. If Biotechnology Assets Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biotechnology Assets is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biotechnology Assets is generally in the same direction as the market. If Beta > 1 Biotechnology Assets moves generally in the same direction as, but more than the movement of the benchmark.
Biotechnology Assets Thematic Clasifications
Biotechnology Assets SA is part of several thematic ideas from Computers to Biotech. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasBiotechnology Assets November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biotechnology Assets help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biotechnology Assets SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biotechnology Assets SA based on widely used predictive technical indicators. In general, we focus on analyzing Biotechnology Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biotechnology Assets's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.8 | |||
| Information Ratio | 0.0251 | |||
| Maximum Drawdown | 49.57 | |||
| Value At Risk | (3.70) | |||
| Potential Upside | 3.57 |
Complementary Tools for Biotechnology Stock analysis
When running Biotechnology Assets' price analysis, check to measure Biotechnology Assets' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotechnology Assets is operating at the current time. Most of Biotechnology Assets' value examination focuses on studying past and present price action to predict the probability of Biotechnology Assets' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotechnology Assets' price. Additionally, you may evaluate how the addition of Biotechnology Assets to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |